MEDIFACTS INTERNATIONAL, INC., one of the largest global providers of
noninvasive cardiovascular diagnostic services, today announced that
they are once again leading the Cardiovascular Safety Services
marketplace in innovation, expertise, and execution - this time with new
innovations in the use of telemedicine, T-SMBP (Telemonitoring Self
Measured Blood Pressure), in clinical trials.
T-SMBP allows for remote collection of blood pressure (BP) data from a
subject’s home. Telemonitoring and telemedicine are actively being
implemented through health care providers for general patient care,
specifically in patients being treated for heart failure, diabetes,
cancer and hypertension. The transition and implementation of
telemedicine in clinical trials provides many benefits to the conduct of
the study. The benefits of implementing T-SMBP include: (i) electronic
capture of BP data, which removes transcription errors; (ii) reduction
in the number of office visits required by the subject; and perhaps most
importantly (iii) real-time access to the subjects’ BP data via study
web portal, which allows for alert criteria process and real-time view
of data trends and treatment effect.